SWOG clinical trial number
CTSU/EAE161

Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Closed
Abbreviated Title
Perfusion CT to Predict PFS and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status Notes
SWOG Activated/Championed CTSU/EAE161, effective March 1, 2019

Closed to accrual, Effective January 9, 2020.
Activated
03/01/2019
Closed
01/08/2020
Participants
CTSU

Research committees

Early Therapeutics & Rare Cancers

Treatment

Olaparib

Eligibility Criteria Expand/Collapse

Please see the CTSU/EAE161 protocol posted on www.ctsu.org for eligibility criteria.

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/AOST2032
SWOG Clinical Trial Number
CTSU/AOST2031